Bacterin to Present at the 5th Annual Maxim Group Growth Conference on March 26, 2012

Published In: Business, Montana, New York 
Monday, March 12, 2012 4:00 PM
< Archive for Jul 2014 >
SuMoTuWeThFrSa
  1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31






Bacterin to Present at the 5th Annual Maxim Group Growth Conference on March 26, 2012

/* Style Definitions */
span.prnews_span
{
font-size:8pt;
font-family:"Arial";
color:black;
}
a.prnews_a
{
color:blue;
}
li.prnews_li
{
font-size:8pt;
font-family:"Arial";
color:black;
}
p.prnews_p
{
font-size:8pt;
font-family:"Arial";
color:black;
}






Bacterin to Present at the 5th Annual Maxim Group Growth Conference on March 26, 2012
PR Newswire
BELGRADE, Mont., March 12, 2012



BELGRADE, Mont., March 12, 2012 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, will present at the 5th Annual Maxim Group Growth Conference, held on Monday, March 26, 2012, at the Grand Hyatt Hotel in New York.

Bacterin's chairman and CEO, Guy Cook, is scheduled to present at 8:30am in the Carnegie room, with one-on-one meetings held throughout the day.

This full-day event will feature approximately 90 different companies having group presentations and 1x1 meeting slots available. These companies span a broad range of sectors, such as Healthcare, Specialty Finance, Energy, Infrastructure, Aerospace, Media & Technology.

For more information about the conference, please contact your Maxim Group sales representative.

About Bacterin International Holdings

Bacterin International Holdings, Inc. (NYSE Amex: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin's Medical Device division develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. For further information, please visit www.bacterin.com.

Important Cautions Regarding Forward-looking Statements

This news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability to launch beta and full product releases, the Company's ability to obtain FDA concurrence use for anti-microbial coatings in a timely manner; the Company's ability to meet its obligations under existing and anticipated contractual obligations; the Company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company's sales force to achieve expected results; the ability of the Company's customers to pay and the timeliness of such payments, particularly during recessionary periods; the Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

 

Contact:

INVESTOR INQUIRIES:

Hayden IR

James Carbonara, Regional Vice President, 646-755-7412

james@haydenir.com

Brett Maas, 646-536-7331

brett@haydenir.com

 
SOURCE Bacterin International Holdings, Inc.








 
Monday, March 12, 2012 4:00 PM

Share Socially:
BlinkListBlinkList del.icio.usdel.icio.us DiggDigg FurlFurl ma.gnoliama.gnolia redditreddit SimpySimpy SpurlSpurl BlogMarksBlogMarks NewsvineNewsvine Share on Facebook Sphere: Related Content

Related Press Releases

FLY Leasing to Present at Maxim Conference on March 26, 2012
Published In: Business, Ireland, New York 
Thursday, March 22, 2012 10:00 AM
Cynosure to Present at the Maxim Group Growth Conference
Published In: Business, Massachusetts 
Wednesday, October 1, 2008 8:30 AM